{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": 11.999997, "regularMarketPrice": 1.68, "exchange": "NCM", "shortName": "ContraFect Corporation", "longName": "ContraFect Corporation", "messageBoardId": "finmb_112206719", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "firstTradeDateMilliseconds": 1410528600000, "tradeable": false, "cryptoTradeable": false, "priceHint": 4, "preMarketChange": 0.0, "preMarketChangePercent": 0.0, "preMarketTime": 1684227667, "preMarketPrice": 1.68, "regularMarketChange": 0.17999995, "regularMarketTime": 1684180804, "regularMarketDayHigh": 1.85, "regularMarketDayRange": "1.5815 - 1.85", "regularMarketDayLow": 1.5815, "regularMarketVolume": 484973, "regularMarketPreviousClose": 1.5, "bid": 0.0, "ask": 0.0, "bidSize": 8, "askSize": 8, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 1.69, "averageDailyVolume3Month": 4289143, "averageDailyVolume10Day": 262740, "fiftyTwoWeekLowChange": 0.78, "fiftyTwoWeekLowChangePercent": 0.8666667, "fiftyTwoWeekRange": "0.9 - 363.2", "fiftyTwoWeekHighChange": -361.52002, "fiftyTwoWeekHighChangePercent": -0.99537444, "fiftyTwoWeekLow": 0.9, "fiftyTwoWeekHigh": 363.2, "dividendDate": 1580774400, "earningsTimestamp": 1684152003, "earningsTimestampStart": 1692016200, "earningsTimestampEnd": 1692361800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -882.14, "epsForward": -2.87, "epsCurrentYear": -9.91, "priceEpsCurrentYear": -0.16952573, "sharesOutstanding": 3669920, "bookValue": -19.92, "fiftyDayAverage": 1.82228, "fiftyDayAverageChange": -0.1422801, "fiftyDayAverageChangePercent": -0.07807807, "twoHundredDayAverage": 9.91032, "twoHundredDayAverageChange": -8.23032, "twoHundredDayAverageChangePercent": -0.83047974, "marketCap": 6987523, "forwardPE": -0.58536583, "priceToBook": -0.084337346, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "displayName": "ContraFect", "symbol": "CFRX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "28 Wells Avenue", "address2": "3rd Floor", "city": "Yonkers", "state": "NY", "zip": "10701", "country": "United States", "phone": "914 207 2300", "website": "https://www.contrafect.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.", "fullTimeEmployees": 23, "companyOfficers": [{"maxAge": 1, "name": "Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.", "age": 65, "title": "Chairman, CEO & Pres", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": {"raw": 970716, "fmt": "970.72k", "longFmt": "970,716"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Michael  Messinger CPA, CPA", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 543138, "fmt": "543.14k", "longFmt": "543,138"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Natalie  Bogdanos J.D.", "age": 53, "title": "Gen. Counsel, Corp. Sec. & Data Protection Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 531204, "fmt": "531.2k", "longFmt": "531,204"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Matthew  Salamone P.H.R., SPHR", "title": "VP of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Gary  Woodnutt", "age": 65, "title": "Sr. VP of Translational Sciences & Preclinical Devel.", "yearBorn": 1957, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 6, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}